FDA Approves Next-Gen BCL2 Inhibitor Sonrotoclax for R/R Mantle Cell LymphomaByPaige BrittMay 13th 2026
ALPHA3 Explores LBCL First-Line Consolidation With Off-the-Shelf Cema-CelByAndrea Eleazar, MHS,Jeff Sharman, MDMay 11th 2026
Pediatric Blood Cancers: Building Better Outcomes Through Bold ScienceByPallav K. Mehta, MD,E. Anders Kolb, MDMay 6th 2026